Multisystem Neuropathology of Parkinson's Disease: A Convergence of Synucleinopathy, Neuroinflammation, And Dopaminergic Demise

A chronic, progressive neurodegenerative illness, Parkinson's disease (PD) is characterized by the destruction of dopaminergic neurons in the substantia nigra pars compacta. This degeneration causes motor symptoms such bradykinesia, stiffness, tremors, and postural instability. As a multisystem condition, Parkinson's disease (PD) is becoming more well acknowledged for its substantial non-motor symptoms, which include mood swings, autonomic dysfunction, sleep issues, cognitive impairment, and sensory abnormalities. Its intricate pathophysiology includes oxidative stress, Lewy body formation, alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation, all of which are impacted by environmental and genetic variables (such as SNCA, LRRK2, and PARKIN mutations). Though familial types do exist, the majority of cases are idiopathic. Although research into biomarkers and neuroimaging is still ongoing, the diagnosis is still mostly clinical.Levodopa, dopamine agonists, and MAO-B inhibitors are used in current treatment to alleviate symptoms, in addition to non-pharmacological methods including physical therapy and deep brain stimulation. There are currently no cures or treatments that alter the condition, despite a great deal of study. In order to enhance patient outcomes, this study emphasizes the necessity of early diagnostic instruments and neuroprotective techniques.